Provided by Tiger Fintech (Singapore) Pte. Ltd.

Chimerix

8.46
-0.0050-0.06%
Volume:951.52K
Turnover:8.04M
Market Cap:760.41M
PE:-9.01
High:8.46
Open:8.43
Low:8.43
Close:8.46
Loading ...

Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma

GlobeNewswire
·
18 Feb

Metalpha Technology Holding And 2 Other US Penny Stocks To Monitor

Simply Wall St.
·
17 Feb

Chimerix’s Strategic Progress and Upcoming Catalysts: A Promising Outlook for 2025

TIPRANKS
·
06 Feb

CMRX Stock Skyrockets in 3 Months: Here's What You Should Know

Zacks
·
31 Jan

Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium

GlobeNewswire
·
30 Jan

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
25 Jan

Here’s Why Chimerix, Inc. (CMRX) Is Skyrocketing

Insider Monkey
·
14 Jan

Chimerix to Speak Today at The White House Cancer Moonshot Forum

GlobeNewswire
·
13 Jan

Chimerix Receives ‘Buy’ Rating from Edward White on Promising Drug Development and Strong Financial Outlook

TIPRANKS
·
30 Dec 2024

Chimerix Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
30 Dec 2024

Promising Outlook for Chimerix: Strategic Developments and Financial Strength Justify Buy Rating

TIPRANKS
·
30 Dec 2024

Chimerix Seeks Accelerated FDA Approval for Experimental Tumor Drug

MT Newswires Live
·
30 Dec 2024

Chimerix Inc - Requests Priority Review for Nda

THOMSON REUTERS
·
30 Dec 2024

Chimerix Inc - Enters Credit Facility of up to $30 Million With Svb

THOMSON REUTERS
·
30 Dec 2024

Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients With Recurrent H3 K27m-Mutant Diffuse Glioma

THOMSON REUTERS
·
30 Dec 2024

Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma

GlobeNewswire
·
30 Dec 2024